Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.
2.

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.

Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM.

J Urol. 1999 Jul;162(1):98-102.

PMID:
10379749
3.

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW.

J Clin Oncol. 2006 Mar 20;24(9):1409-14. Epub 2006 Feb 27.

PMID:
16505409
4.

Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial.

Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB.

Obstet Gynecol. 2005 Jan;105(1):161-6.

PMID:
15625158
5.

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

Vitolins MZ, Griffin L, Tomlinson WV, Vuky J, Adams PT, Moose D, Frizzell B, Lesser GJ, Naughton M, Radford JE Jr, Shaw EG.

J Clin Oncol. 2013 Nov 10;31(32):4092-8. doi: 10.1200/JCO.2012.48.1432. Epub 2013 Sep 30.

6.

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ.

Lancet. 2000 Dec 16;356(9247):2059-63.

PMID:
11145492
7.

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.

Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P.

Lancet Oncol. 2012 Dec;13(12):1260-70. doi: 10.1016/S1470-2045(12)70423-0. Epub 2012 Nov 12. Erratum in: Lancet Oncol. 2014 Sep;15(10):e417. Dosage error in article text.

PMID:
23151431
8.

Interventions for hirsutism (excluding laser and photoepilation therapy alone).

van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N.

Cochrane Database Syst Rev. 2015 Apr 28;(4):CD010334. doi: 10.1002/14651858.CD010334.pub2. Review.

9.

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L.

Lancet Oncol. 2010 Nov;11(11):1066-73. doi: 10.1016/S1470-2045(10)70223-0. Epub 2010 Oct 7.

PMID:
20933466
10.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH.

J Clin Oncol. 2011 Oct 10;29(29):3862-8. doi: 10.1200/JCO.2010.33.1298. Epub 2011 Sep 12.

PMID:
21911720
11.

Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.

Speroff L, Gass M, Constantine G, Olivier S; Study 315 Investigators.

Obstet Gynecol. 2008 Jan;111(1):77-87. doi: 10.1097/01.AOG.0000297371.89129.b3.

PMID:
18165395
12.

Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial.

Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, Freeman EW, Larson JC, Manson JE, LaCroix AZ, Guthrie KA.

Obstet Gynecol. 2014 Aug;124(2 Pt 1):233-41. doi: 10.1097/AOG.0000000000000386.

13.
14.

Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.

Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T, Lance R, Thrasher JB.

J Urol. 2005 Aug;174(2):642-5.

PMID:
16006929
15.

Managing hot flashes in men being treated for prostate cancer.

Baum NH, Torti DC.

Geriatrics. 2007 Nov;62(11):18-21. Review.

PMID:
17999566
16.

'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.

Cervenákov I, Kopecný M, Jancár M, Chovan D, Mal'a M.

Int Urol Nephrol. 2000;32(1):77-9.

PMID:
11057778
17.

[Therapy of vasomotor syndrome in the treatment of advanced prostatic cancer: apropos of 37 cases].

Ronzoni G, De Giovanni L, Menchinelli P, Meneschincheri M.

Arch Ital Urol Androl. 1998 Feb;70(1):37-40. Italian.

PMID:
9549167
18.

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study.

Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M.

Ann Oncol. 2007 Apr;18(4):689-93. Epub 2007 Jan 17.

PMID:
17229772
19.

Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors.

Biglia N, Torta R, Roagna R, Maggiorotto F, Cacciari F, Ponzone R, Kubatzki F, Sismondi P.

Maturitas. 2005 Sep 16;52(1):78-85.

PMID:
16143229
20.

Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer--a prospective multicenter study with long-term follow-up.

Frisk J, Spetz AC, Hjertberg H, Petersson B, Hammar M.

Eur Urol. 2009 Jan;55(1):156-63. doi: 10.1016/j.eururo.2008.02.002. Epub 2008 Feb 14.

PMID:
18294761

Supplemental Content

Support Center